Watch Sanjay popat discuss the QoL results of the LUX-Lung 3 trial!
GIOTRIF® (afatinib) significantly improved dyspnoea and some pain symptoms compared with pemetrexed/cisplatin1
- More patients (≥50%) on GIOTRIF® (afatinib) experienced clinically meaningful improvements in pre-specified tumour symptoms (dyspnoea, pain and cough)1
GIOTRIF® (afatinib) delayed time to worsening of clinically relevant symptoms versus pemetrexed/cisplatin1
Compared with chemotherapy, GIOTRIF® (afatinib) delayed time to deterioration of cough (27 vs 8 months, P=0.006), dyspnoea (10.4 vs 2.9 months, P=0.013) and pain (4.2 vs 3.1 months, P=0.188), respectively2
GIOTRIF® (afatinib) significantly improved QoL versus pemetrexed/cisplatin1
- GIOTRIF® (afatinib) had significantly better mean QoL scores over time for global health status/QoL, physical role, and cognitive functioning1
CI=confidence interval; EGFR M+=epidermal growth factor receptor mutation positive; EORTC=European Organisation for Research and Treatment of Cancer; QoL=quality of life; TTD=time to deterioration, the time from randomisation to first appearance of a score ≥10 points lower than the baseline score.